Comparing Two CAR-T Therapies: Liso-cel and Axi-cel in LBCL
At a single hospital, patients with large B-cell lymphoma (LBCL) who didn't respond to initial treatments were given either lisocabtagene maraleucel (liso-cel) or axicabtagene ciloleucel (axi-cel). Liso-cel is newer and not widely studied outside clinical trials yet. From June 2021 to September 2022